Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cessation of Antiplatelet Therapy May Increase Severity of Cardiac Events

This article was originally published in The Tan Sheet

Executive Summary

Coronary artery disease patients who recently stopped use of aspirin or other antiplatelet therapy are at greater risk of death and death/heart attack combined compared to both nonusers and prior users, a study published in the Oct. 19 Circulation finds

You may also be interested in...



Aspirin Therapy Interruption Linked To Higher Stroke Risk In Survivors

Former stroke sufferers who interrupted aspirin therapy regimens exhibited more than a three-fold increase in risk of a second stroke, according to a study presented Feb. 2 at an American Stroke Association conference in New Orleans

Aspirin Therapy Interruption Linked To Higher Stroke Risk In Survivors

Former stroke sufferers who interrupted aspirin therapy regimens exhibited more than a three-fold increase in risk of a second stroke, according to a study presented Feb. 2 at an American Stroke Association conference in New Orleans

Aspirin Therapy Interruption Linked To Higher Stroke Risk In Survivors

Former stroke sufferers who interrupted aspirin therapy regimens exhibited more than a three-fold increase in risk of a second stroke, according to a study presented Feb. 2 at an American Stroke Association conference in New Orleans

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel